Nhancer Rx
Payments companies reported to CMS as associated with Nhancer Rx. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Nhancer Rx, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Nhancer Rx
These are the largest totals companies reported as associated with Nhancer Rx. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sasrutha Wickramasinghe | Houston, TX | Cardiovascular Disease | $10,496.10 |
| Robert Stoler | Dallas, TX | Interventional Cardiology | $9,603.88 |
| Rajiv Jauhar | New Hyde Park, NY | Cardiovascular Disease | $6,820.82 |
| Aditya Sharma | Carlisle, PA | Interventional Cardiology | $6,349.12 |
| Ajay Kirtane | New York, NY | Interventional Cardiology | $5,332.00 |
| Aziz Maksoud | Wichita, KS | Cardiovascular Disease | $759.00 |
| Manish Parikh | Brooklyn, NY | Internal Medicine | $683.42 |
| Alpesh Shah | Pearland, TX | Interventional Cardiology | $652.47 |
| Arzhang Fallahi | Stamford, CT | Interventional Cardiology | $652.47 |
| Garrett Wong | Sacramento, CA | Cardiovascular Disease | $532.31 |
Prescribed Nhancer Rx?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.